Cannabinoids-based pharmaceutical company MediPharm Labs Corp. LABS MEDIF MLZ announced on Thursday that it has entered into a licensing agreement with Remidose Aerosols Inc. to acquire the exclusive rights for advanced cannabis products.
Under the deal, current Remidose customers will be serviced through MediPharm starting August 2024, including Canadian direct-to-patient medical platforms and international medical distributors.
MediPharm intends to utilize its existing GMP infrastructure, customer channels and wellness sales expertise to expand the customer base of these advanced products in Canada and internationally.
Learn more about innovation in cannabis at the upcoming Benzinga cannabis event. The 19th Benzinga Cannabis Capital Conference, returns to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.
The products in question are split into two main categories, including:
- Metered Dose Inhalers. Why? Used in the pharmaceutical industry as well, this inhalation format provides rapid onset without the adverse effects of smoking.
- Pressurized Sublingual Sprays. Why? Providing users with an accurate and repeatable experience, this aerosol delivery method has a faster onset, better bioavailability and a more pleasant taste and feel.
“MediPharm Labs is committed to providing access to non-smokeable, precision-dosed formats for cannabis patients and wellness consumers," David Pidduck, CEO of MediPharm said. "This agreement, in addition to bringing immediate revenue, opens many new potential global medical opportunities."
MediPharm already has the requisite equipment and GMP facility for these product lines to be manufactured in-house with no material incremental capital costs.
Now read: This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.